Tag: anthracycline

Articles

• Factors influencing Adriamycin (doxorubicin) effectiveness
• Foods to eat and avoid during Adriamycin chemotherapy

News

05/30/12

Fish oil might promote Adriamycin-induced heart damage

02/15/12

Grapes might help protect against Adriamycin-induced heart damage

12/15/11

Kaempferol protects against Adriamycin-induced heart damage

12/07/11

Modern chemotherapy reduces BC death by about a third

12/01/11

Herceptin + anthracycline chemo increases risk of cardiomyopathy

11/09/11

Curcumin reduces breast cancer resistance to Adriamycin

09/24/11

Caffeine may reduce the effectiveness of Adriamycin chemotherapy

07/11/11

Taking Celebrex might reduce effectiveness of chemotherapy

11/03/10

Chemotherapy resistance is accompanied by more BC stem cells

Studies

• Abstract 4147821: Physical Activity Impacts Cardiac Tissue Mitochondrial Respiration During Anthracycline Chemotherapy Cite
  Riojas A, Harbert S, Lacy J, Piloso J, Kramer P, Weis J, et al. Abstract 4147821: Physical Activity Impacts Cardiac Tissue Mitochondrial Respiration During Anthracycline Chemotherapy. Circulation. Ovid Technologies (Wolters Kluwer Health); 2024; 150 10.1161/circ.150.suppl_1.4147821
• Effects of exercise therapy on chemotherapy delivery and response in primary breast cancer: A secondary analysis of a randomized trial Cite
  Iyengar NM, Scott JM, Lee J, Lavery JA, Foug KL, Lee CP, et al. Effects of exercise therapy on chemotherapy delivery and response in primary breast cancer: A secondary analysis of a randomized trial. Cancer. Wiley; 2024; 10.1002/cncr.35575
• Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience Cite
  Singareeka Raghavendra A, Liu D, Shen Y, Barcenas CH, Ueno NT, Giordano S, et al. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07309-7
• Statin use is associated with a lower risk of all-cause death in patients with breast cancer treated with anthracycline containing regimens: a global federated health database analysis Cite
  Bucci T, Gue Y, Dobson R, Palmieri C, Pignatelli P, Lip GYH. Statin use is associated with a lower risk of all-cause death in patients with breast cancer treated with anthracycline containing regimens: a global federated health database analysis. Clinical and Experimental Medicine. Springer Science and Business Media LLC; 2024; 24 10.1007/s10238-024-01395-z
• Potential of Natural Phenolic Compounds against Doxorubicin-Induced Chemobrain: Biological and Molecular Mechanisms Involved Cite
  Serini S, Calviello G. Potential of Natural Phenolic Compounds against Doxorubicin-Induced Chemobrain: Biological and Molecular Mechanisms Involved. Antioxidants. MDPI AG; 2024; 13:486 10.3390/antiox13040486
• Statin use is associated with a lower risk of mortality in patients with malignant breast cancer treated with anthracyclines. A global federated health database analysis Cite
  Bucci T, Gue Y, Dobson R, Palmieri C, Pignatelli P, Cross M, et al. Statin use is associated with a lower risk of mortality in patients with malignant breast cancer treated with anthracyclines. A global federated health database analysis. European Heart Journal. Oxford University Press (OUP); 2023; 44 10.1093/eurheartj/ehad655.2876
• Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer Cite
  Wang Y, Ronckers CM, van Leeuwen FE, Moskowitz CS, Leisenring W, Armstrong GT, et al. Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. Nature Medicine. Springer Science and Business Media LLC; 2023; 29:2268-2277 10.1038/s41591-023-02514-1
• Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients Cite
  Balaji S, Antony AK, Tonchev H, Scichilone G, Morsy M, Deen H, et al. Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients. Biomedicines. MDPI AG; 2023; 11:2286 10.3390/biomedicines11082286
• Redefining the “crown”: Approaching chemotherapy‐induced alopecia among Black patients with breast cancer Cite
  Pleasant VA, Purkiss AS, Merjaver SD. Redefining the “crown”: Approaching chemotherapy‐induced alopecia among Black patients with breast cancer. Cancer. Wiley; 2023; 129:1629-1633 10.1002/cncr.34732
• Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010 Cite
  Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, et al. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010. JAMA Network Open. American Medical Association (AMA); 2023; 6:e2254669 10.1001/jamanetworkopen.2022.54669
• The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2—A Systematic Review Cite
  Krejbich P, Birringer M. The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2—A Systematic Review. Antioxidants. MDPI AG; 2022; 11:2149 10.3390/antiox11112149
• Exercise for the Prevention of Anthracycline-induced Functional Disability and Cardiac Dysfunction: The BReast Cancer Randomized EXercise InTervention (BREXIT) Study Cite
  Foulkes SJ, Howden EJ, Haykowsky MJ, Antill Y, Salim A, Nightingale SS, et al. Exercise for the Prevention of Anthracycline-induced Functional Disability and Cardiac Dysfunction: The BReast Cancer Randomized EXercise InTervention (BREXIT) Study. Circulation. Ovid Technologies (Wolters Kluwer Health); 2022; 10.1161/circulationaha.122.062814
• The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial Cite
  Barakat HE, Hussein RRS, Elberry AA, Zaki MA, Ramadan ME. The impact of metformin use on the outcomes of locally advanced breast cancer patients receiving neoadjuvant chemotherapy: an open-labelled randomized controlled trial. Scientific Reports. Springer Science and Business Media LLC; 2022; 12 10.1038/s41598-022-11138-3
• Diet impacts triple‐negative breast cancer growth, metastatic potential, chemotherapy responsiveness, and doxorubicin‐mediated cardiac dysfunction Cite
  Ramirez MU, Clear KYJ, Cornelius Z, Bawaneh A, Feliz‐Mosquea YR, Wilson AS, et al. Diet impacts triple‐negative breast cancer growth, metastatic potential, chemotherapy responsiveness, and doxorubicin‐mediated cardiac dysfunction. Physiological Reports. Wiley; 2022; 10 10.14814/phy2.15192
• Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study Cite
  Greenlee H, Iribarren C, Rana JS, Cheng R, Nguyen-Huynh M, Rillamas-Sun E, et al. Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 10.1200/jco.21.01736
• Trends in heart disease mortality among breast cancer survivors in the US, 1975–2017 Cite
  Vo JB, Ramin C, Barac A, Berrington de Gonzalez A, Veiga L. Trends in heart disease mortality among breast cancer survivors in the US, 1975–2017. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06515-5
• A careful reassessment of anthracycline use in curable breast cancer Cite
  Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, et al. A careful reassessment of anthracycline use in curable breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00342-5
• Focal white matter microstructural alteration after anthracycline-based systemic treatment in long-term breast cancer survivors: a structural magnetic resonance imaging study Cite
  Zhang H, Li P, Liu T, Wang X, Feng W, Chen R, et al. Focal white matter microstructural alteration after anthracycline-based systemic treatment in long-term breast cancer survivors: a structural magnetic resonance imaging study. Brain Imaging and Behavior. Springer Science and Business Media LLC; 2021; 10.1007/s11682-021-00551-3
• Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study Cite
  Abdel‐Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo‐Argüelles O, Amir E, et al. Statin Exposure and Risk of Heart Failure After Anthracycline‐ or Trastuzumab‐Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study. Journal of the American Heart Association. Ovid Technologies (Wolters Kluwer Health); 2021; 10.1161/jaha.119.018393
• Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study Cite
  Jacobse JN, Schaapveld M, Boekel NB, Hooning MJ, Jager A, Baaijens MHA, et al. Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05930-w
• Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients– the BReast cancer EXercise InTervention (BREXIT) trial protocol Cite
  Foulkes SJ, Howden EJ, Antill Y, Loi S, Salim A, Haykowsky MJ, et al. Exercise as a diagnostic and therapeutic tool for preventing cardiovascular morbidity in breast cancer patients– the BReast cancer EXercise InTervention (BREXIT) trial protocol. BMC Cancer. Springer Science and Business Media LLC; 2020; 20 10.1186/s12885-020-07123-6
• Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer Cite
  Cespedes Feliciano EM, Chen WY, Lee V, Albers KB, Prado CM, Alexeeff S, et al. Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer. JAMA Oncology. American Medical Association (AMA); 2020; 6:264 10.1001/jamaoncol.2019.4668
• Exercise Intolerance in Anthracycline‐Treated Breast Cancer Survivors: The Role of Skeletal Muscle Bioenergetics, Oxygenation, and Composition Cite
  Beaudry RI, Kirkham AA, Thompson RB, Grenier JG, Mackey JR, Haykowsky MJ. Exercise Intolerance in Anthracycline‐Treated Breast Cancer Survivors: The Role of Skeletal Muscle Bioenergetics, Oxygenation, and Composition. The Oncologist. Wiley; 2020; 25 10.1634/theoncologist.2019-0777
• Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study Cite
  Kaboré EG, Guenancia C, Vaz-Luis I, Di Meglio A, Pistilli B, Coutant C, et al. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. PLOS Medicine. Public Library of Science (PLoS); 2019; 16:e1002989 10.1371/journal.pmed.1002989
• Combined effect of radiotherapy and anthracyclines on risk of breast cancer among female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS). Cite
  Veiga LHS, Curtis RE, Morton LM, Withrow D, Howell RM, Smith SA, et al. Combined effect of radiotherapy and anthracyclines on risk of breast cancer among female childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS).. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:10053-10053 10.1200/jco.2019.37.15_suppl.10053
• Subsequent Breast Cancer in Female Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE) Cite
  Ehrhardt MJ, Howell CR, Hale K, Baassiri MJ, Rodriguez C, Wilson CL, et al. Subsequent Breast Cancer in Female Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:1647-1656 10.1200/jco.18.01099
• A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients Cite
  Watanabe T, Yagata H, Saito M, Okada H, Yajima T, Tamai N, et al. A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients. PLOS ONE. Public Library of Science (PLoS); 2019; 14:e0208118 10.1371/journal.pone.0208118
• Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment Cite
  Amézaga J, Alfaro B, Ríos Y, Larraioz A, Ugartemendia G, Urruticoechea A, et al. Assessing taste and smell alterations in cancer patients undergoing chemotherapy according to treatment. Supportive Care in Cancer. Springer Science and Business Media LLC; 2018; 26:4077-4086 10.1007/s00520-018-4277-z
• COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer Cite
  Smetanay K, Junio P, Feißt M, Seitz J, Hassel JC, Mayer L, et al. COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 173:135-143 10.1007/s10549-018-4983-8
• Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients Cite
  Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC: Cardiovascular Imaging. Elsevier BV; 2018; 11:1084-1093 10.1016/j.jcmg.2018.06.005
• Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database Cite
  Choi JY, Cho EY, Choi YJ, Lee JH, Jung SP, Cho KR, et al. Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 171:181-188 10.1007/s10549-018-4809-8
• Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity Cite
  Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, das Dores Cruz F, Gonçalves Brandão SM, Rigaud VOC, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity. Journal of the American College of Cardiology. Elsevier BV; 2018; 71:2281-2290 10.1016/j.jacc.2018.02.049
• Phenolic content, anthocyanins and antiradical capacity of diverse purple bran rice genotypes as compared to other bran colors Cite
  Chen M, McClung AM, Bergman CJ. Phenolic content, anthocyanins and antiradical capacity of diverse purple bran rice genotypes as compared to other bran colors. Journal of Cereal Science. Elsevier BV; 2017; 77:110-119 10.1016/j.jcs.2017.07.010
• Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study Cite
  Boyd A, Stoodley P, Richards D, Hui R, Harnett P, Vo K, et al. Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. PLOS ONE. Public Library of Science (PLoS); 2017; 12:e0175544 10.1371/journal.pone.0175544
• Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis Cite
  Abdel-Qadir H, Ong G, Fazelzad R, Amir E, Lee D, Thavendiranathan P, et al. Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis. Annals of Oncology. Elsevier BV; 2017; 28:628-633 10.1093/annonc/mdw671
• Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers Cite
  Henninger C, Fritz G. Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death & Disease. Springer Science and Business Media LLC; 2017; 8:e2564-e2564 10.1038/cddis.2016.418
• BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer Cite
  Mori H, Kubo M, Nishimura R, Osako T, Arima N, Okumura Y, et al. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0167016 10.1371/journal.pone.0167016
• Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early stage breast cancer. Cite
  Nangia JR, Wang T, Osborne CRC, Niravath PA, Otte K, Papish SW, et al. Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early stage breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:10088-10088 10.1200/jco.2017.35.15_suppl.10088
• Results of scalp cooling during anthracycline containing chemotherapy depend on scalp skin temperature Cite
  Komen M, Smorenburg C, Nortier J, van der Ploeg T, van den Hurk C, van der Hoeven J. Results of scalp cooling during anthracycline containing chemotherapy depend on scalp skin temperature. The Breast. Elsevier BV; 2016; 30:105-110 10.1016/j.breast.2016.09.007
• Serum IL-6 level as a predictor of response to neo-Adjuvant chemotherapy in patients of breast carcinoma Cite
  Mittal P, Gupta N, Goswami B. Serum IL-6 level as a predictor of response to neo-Adjuvant chemotherapy in patients of breast carcinoma. Hellenic Journal of Surgery. Springer Science and Business Media LLC; 2016; 88:306-310 10.1007/s13126-016-0338-2
• Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis Cite
  Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, et al. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:3157-3165 10.1200/jco.2016.67.4846
• Abstract 260: Quercetin protects from doxorubicin induced vascular toxicity but impairs its cytotoxic profile in breast cancer cells Cite
  Assiri HA, Al-Abbasi FA, El-Bassossy HM, El-Moselhy MA, Al-Abd AM. Abstract 260: Quercetin protects from doxorubicin induced vascular toxicity but impairs its cytotoxic profile in breast cancer cells. Experimental and Molecular Therapeutics. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-260
• Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer Cite
  De Iuliis F, Salerno G, Corvino R, D'Aniello D, Cefalì K, Taglieri L, et al. Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2017; 17:34-40 10.1016/j.clbc.2016.06.010
• Comparison of Neurocognitive Function After Anthracycline-Based Chemotherapy vs Nonanthracycline-Based Chemotherapy Cite
  Van Dyk K, Petersen L, Ganz PA. Comparison of Neurocognitive Function After Anthracycline-Based Chemotherapy vs Nonanthracycline-Based Chemotherapy. JAMA Oncology. American Medical Association (AMA); 2016; 2:964 10.1001/jamaoncol.2016.0350
• Breast Cancer Therapy–Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study Cite
  Thavendiranathan P, Abdel-Qadir H, Fischer HD, Camacho X, Amir E, Austin PC, et al. Breast Cancer Therapy–Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:2239-2246 10.1200/jco.2015.65.1505
• Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors Cite
  Kesler SR, Blayney DW. Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors. JAMA Oncology. American Medical Association (AMA); 2016; 2:185 10.1001/jamaoncol.2015.4333
• Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors Cite
  Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, et al. Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2016; 94:1061-1072 10.1016/j.ijrobp.2015.11.040
• The flavonoid quercetin: Possible solution for anthracycline-induced cardiotoxicity and multidrug resistance Cite
  Czepas J, Gwoździński K. The flavonoid quercetin: Possible solution for anthracycline-induced cardiotoxicity and multidrug resistance. Biomedicine & Pharmacotherapy. Elsevier BV; 2014; 68:1149-1159 10.1016/j.biopha.2014.10.013
• Chronic heart damage following doxorubicin treatment is alleviated by lovastatin Cite
  Henninger C, Huelsenbeck S, Wenzel P, Brand M, Huelsenbeck J, Schad A, et al. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin. Pharmacological Research. Elsevier BV; 2015; 91:47-56 10.1016/j.phrs.2014.11.003
• Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer Cite
  Barcenas CH, Niu J, Zhang N, Zhang Y, Buchholz TA, Elting LS, et al. Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014; 32:2010-2017 10.1200/jco.2013.49.3676
• Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial Cite
  Bonnefoi H, Litière S, Piccart M, MacGrogan G, Fumoleau P, Brain E, et al. Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial. Annals of Oncology. Elsevier BV; 2014; 25:1128-1136 10.1093/annonc/mdu118
• Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation Cite
  Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Prasad SVN, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. Journal of Clinical Investigation. American Society for Clinical Investigation; 2014; 124:617-630 10.1172/jci72931
• Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis Cite
  Pajares B, Pollán M, Martín M, Mackey JR, Lluch A, Gavila J, et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Research. Springer Science and Business Media LLC; 2013; 15 10.1186/bcr3572
• Changes in body weight during various types of chemotherapy in breast cancer patients Cite
  Winkels RM, Beijer S, van Lieshout R, van Barneveld D, Hofstede J, Kuiper J, et al. Changes in body weight during various types of chemotherapy in breast cancer patients. e-SPEN Journal. Elsevier BV; 2014; 9:e39-e44 10.1016/j.clnme.2013.10.004
• Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity Cite
  Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, et al. Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline Cardiotoxicity. The American Journal of Cardiology. Elsevier BV; 2013; 112:1980-1984 10.1016/j.amjcard.2013.08.026
• Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis Cite
  Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C, et al. Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis. The Oncologist. Wiley; 2013; 18:667-674 10.1634/theoncologist.2012-0350
• AFRICAN AMERICAN RACE IS A CORRELATE OF HEART FAILURE IN BREAST CANCER SURVIVORS: A STUDY OF 26,347 WOMEN IDENTIFIED WITH BREAST CANCER FROM 1973-2007 Cite
  Valina-Toth AL, Zavodnik T, Seicean S, Plana J, Marwick T. AFRICAN AMERICAN RACE IS A CORRELATE OF HEART FAILURE IN BREAST CANCER SURVIVORS: A STUDY OF 26,347 WOMEN IDENTIFIED WITH BREAST CANCER FROM 1973-2007. Journal of the American College of Cardiology. Elsevier BV; 2013; 61:E580 10.1016/s0735-1097(13)60580-x
• Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer Cite
  Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer. Journal of the American College of Cardiology. Elsevier BV; 2012; 60:2504-2512 10.1016/j.jacc.2012.07.068
• Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study Cite
  Bowles EJA, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2012; 104:1293-1305 10.1093/jnci/djs317
• Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel Cite
  Berliere M, Dalenc F, Malingret N, Vindevogel A, Piette P, Roche H, et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer. Springer Science and Business Media LLC; 2008; 8 10.1186/1471-2407-8-56
• Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens Cite
  Pérez-Fidalgo JA, Roselló S, García-Garré E, Jordá E, Martín-Martorell P, Bermejo B, et al. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 120:245-251 10.1007/s10549-009-0426-x
• Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer Cite
  Swain SM, Jeong J, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, et al. Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2010; 362:2053-2065 10.1056/nejmoa0909638
• Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity Cite
  El-Demerdash E, Ali AA, El-Taher DE, Hamada FM. Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity. Journal of Pharmacy and Pharmacology. Wiley; 2011; 64:344-352 10.1111/j.2042-7158.2011.01413.x
• Grape Seed and Skin Extract Protects Against Acute Chemotherapy Toxicity induced by Doxorubicin in Rat Heart Cite
  Mokni M, Hamlaoui-Guesmi S, Amri M, Marzouki L, Limam F, Aouani E. Grape Seed and Skin Extract Protects Against Acute Chemotherapy Toxicity induced by Doxorubicin in Rat Heart. Cardiovascular Toxicology. Springer Science and Business Media LLC; 2012; 12:158-165 10.1007/s12012-012-9155-1
• Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats Cite
  Swamy A, Gulliaya S, Thippeswamy A, Koti B, Manjula D. Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian Journal of Pharmacology. Medknow; 2012; 44:73 10.4103/0253-7613.91871
• Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles Cite
  Duan J, Mansour HM, Zhang Y, Deng X, Chen Y, Wang J, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. International Journal of Pharmaceutics. Elsevier BV; 2012; 426:193-201 10.1016/j.ijpharm.2012.01.020
• Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro Cite
  Xiao J, Sun G, Sun B, Wu Y, He L, Wang X, et al. Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. Toxicology. Elsevier BV; 2012; 292:53-62 10.1016/j.tox.2011.11.018
• Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Cite
  Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. The Lancet. Elsevier BV; 2012; 379:432-444 10.1016/s0140-6736(11)61625-5
• C-B2-01: Cardiotoxic Chemotherapy is Associated with Increased Heart Failure Risk Among Women with Breast Cancer in the Cancer Research Network Cite
  Bowles EA, Wellman R, Delate T, Allen L, Feigelson HS, Yood MU, et al. C-B2-01: Cardiotoxic Chemotherapy is Associated with Increased Heart Failure Risk Among Women with Breast Cancer in the Cancer Research Network. Clinical Medicine & Research. Marshfield Clinic Research Foundation; 2011; 9:148-148 10.3121/cmr.2011.1020.c-b2-01
• Curcumin Enhances the Efficacy of Chemotherapy by Tailoring p65NFκB-p300 Cross-talk in Favor of p53-p300 in Breast Cancer Cite
  Sen GS, Mohanty S, Hossain DMS, Bhattacharyya S, Banerjee S, Chakraborty J, et al. Curcumin Enhances the Efficacy of Chemotherapy by Tailoring p65NFκB-p300 Cross-talk in Favor of p53-p300 in Breast Cancer. Journal of Biological Chemistry. American Society for Biochemistry & Molecular Biology (ASBMB); 2011; 286:42232-42247 10.1074/jbc.m111.262295
• Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer Cite
  Han Y, Yu Z, Wen S, Zhang B, Cao X, Wang X. Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 131:483-490 10.1007/s10549-011-1799-1
• Adjuvant Trastuzumab in HER2-Positive Breast Cancer Cite
  Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2011; 365:1273-1283 10.1056/nejmoa0910383
• Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer Cite
  Bayraktar S, Gonzalez-Angulo AM, Lei X, Buzdar AU, Valero V, Melhem-Bertrandt A, et al. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. Wiley; 2011; 118:2385-2393 10.1002/cncr.26555
• Synchronous Chemo-radiation Can Reduce Local Recurrence in Early Stage Breast Cancer: Results of the SECRAB Trial (ISRCTN: 84214355) Presented on Behalf of the SECRAB Steering Committee Cite
  Fernando I, Bowden S, Brookes C, Grieve R, Spooner D, Agrawal R, et al. Synchronous Chemo-radiation Can Reduce Local Recurrence in Early Stage Breast Cancer: Results of the SECRAB Trial (ISRCTN: 84214355) Presented on Behalf of the SECRAB Steering Committee. European Journal of Cancer. Elsevier BV; 2011; 47:2 10.1016/s0959-8049(11)70097-1
• Attenuation of Cytotoxic Natural Product DNA Intercalating Agents by Caffeine Cite
  Hill GM. Attenuation of Cytotoxic Natural Product DNA Intercalating Agents by Caffeine. Scientia Pharmaceutica. MDPI AG; 2011; 79:729-747 10.3797/scipharm.1107-19
• Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy. Cite
  Takita C, Reis IM, Miao F, LaFave KE, Gunaseelan V, Hurley J, et al. Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:112-112 10.1200/jco.2011.29.27_suppl.112
• Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells Cite
  El-Awady RA, Saleh EM, Ezz M, Elsayed AM. Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells. Toxicology and Applied Pharmacology. Elsevier BV; 2011; 255:271-286 10.1016/j.taap.2011.06.019
• Pathology of late-onset anthracycline cardiomyopathy Cite
  Bernaba BN, Chan JB, Lai CK, Fishbein MC. Pathology of late-onset anthracycline cardiomyopathy. Cardiovascular Pathology. Elsevier BV; 2010; 19:308-311 10.1016/j.carpath.2009.07.004
• Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Cite
  Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. Wiley; 2011; 13:1-10 10.1093/eurjhf/hfq213
• Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials Cite
  von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 125:145-156 10.1007/s10549-010-1228-x
• Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics Cite
  Calcagno AM, Salcido CD, Gillet J, Wu C, Fostel JM, Mumau MD, et al. Prolonged Drug Selection of Breast Cancer Cells and Enrichment of Cancer Stem Cell Characteristics. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:1637-1652 10.1093/jnci/djq361
• The impact of young age on breast cancer outcome Cite
  Livi L, Meattini I, Saieva C, Borghesi S, Scotti V, Petrucci A, et al. The impact of young age on breast cancer outcome. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2010; 36:639-645 10.1016/j.ejso.2010.05.016
• Early identification of trastuzumab-related cardiotoxicity with speckle-tracking echocardiography. Cite
  Maurea N, De Lorenzo C, Coppola C, Ragone G, Di Pietro E, Schiattarella G, et al. Early identification of trastuzumab-related cardiotoxicity with speckle-tracking echocardiography.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e11096-e11096 10.1200/jco.2010.28.15_suppl.e11096
• Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer. Cite
  Santos FN, Cruz MR, Cezana L, Costa LA, de Azevedo CA, De Barros E Silva MJ, et al. Hematologic toxicity with adjuvant docetaxel and cyclophosphamide in early breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e11081-e11081 10.1200/jco.2010.28.15_suppl.e11081
• Late pancreatic toxicity in patients with breast cancer after taxane-anthracycline–based neoadjuvant and adjuvant chemotherapy. Cite
  Kopp MV, Koroleva I, Kasulin AN, Kucheryavyy JA, Byakhov MJ. Late pancreatic toxicity in patients with breast cancer after taxane-anthracycline–based neoadjuvant and adjuvant chemotherapy.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e11043-e11043 10.1200/jco.2010.28.15_suppl.e11043
• Hepatotoxicity in breast cancer patients post-chemotherapy with docetaxel, doxorubucin, and cyclophosphamide. Cite
  Wills SM, Reid R, Jaiyesimi IA, Margolis JH. Hepatotoxicity in breast cancer patients post-chemotherapy with docetaxel, doxorubucin, and cyclophosphamide.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:e11031-e11031 10.1200/jco.2010.28.15_suppl.e11031
• Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats Cite
  Alkreathy H, Damanhouri ZA, Ahmed N, Slevin M, Ali SS, Osman AM. Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats. Food and Chemical Toxicology. Elsevier BV; 2010; 48:951-956 10.1016/j.fct.2010.01.005
• Patterns of Local and Distant Disease Relapse in Patients with Breast Cancer Treated with Primary Chemotherapy: Do Patients with a Complete Pathological Response Differ from Those with Residual Tumour in the Breast? Cite
  Chaturvedi S, McLaren C, Schofield AC, Ogston KN, Sarkar TK, Hutcheon AW, et al. Patterns of Local and Distant Disease Relapse in Patients with Breast Cancer Treated with Primary Chemotherapy: Do Patients with a Complete Pathological Response Differ from Those with Residual Tumour in the Breast?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2005; 93:151-158 10.1007/s10549-005-4615-y
• Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission Cite
  Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission. Cancer Research. American Association for Cancer Research (AACR); 2009; 69:7507-7511 10.1158/0008-5472.can-09-2994
• Differential modulation of cisplatin and doxorubicin efficacies in leukemia cells by flavonoids Cite
  Čipák L, Novotný L, Čipáková I, Rauko P. Differential modulation of cisplatin and doxorubicin efficacies in leukemia cells by flavonoids. Nutrition Research. Elsevier BV; 2003; 23:1045-1057 10.1016/s0271-5317(03)00078-2